Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03444298 · ClinicalTrials.gov registry record · Phase 2
A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03444298 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 16 participants.
The verdict
NCT03444298, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Purpose: To determine the efficacy of 1400 mg gamma tocopherol-enriched supplement for mitigating inhaled wood smoke particle-induced airway inflammation in healthy adults with no more than mild asthma.
Interventions
- DRUG Placebo
- DRUG Gamma Tocopherol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2023-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03444298
The ClinicalTrials.gov registry entry for NCT03444298 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03444298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03444298 about?
NCT03444298 is a clinical study titled "A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults". Purpose: To determine the efficacy of 1400 mg gamma tocopherol-enriched supplement for mitigating inhaled wood smoke particle-induced airway inflammation in healthy adults with no more than mild asthma.
What is the current status of trial NCT03444298?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-06-08. Estimated completion is 2023-03-06.
What interventions are being tested in trial NCT03444298?
The interventions under investigation include: Placebo (DRUG), Gamma Tocopherol (DRUG).
Who is sponsoring clinical trial NCT03444298?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.